MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.
-
Authors
-
-
Si, Pilei1
-
Shi, Jinjin2
-
Zhang, Pei3
-
Wang, Cao4
-
Chen, Haijun4
-
Mi, Xuefang4
-
Chu, Wenling4
-
Zhai, Baoping1
-
Li, Wentao5
-
1
Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Henan University People's Hospital, Zhengzhou, 450003, China.
,
(China)
-
2
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
,
(China)
-
3
Henan Provincial Food and Drug Evaluation and Inspection Center, Henan Food and Drug Administration, Zhengzhou, 450008, China.
,
(China)
-
4
Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China.
,
(China)
-
5
Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Henan University People's Hospital, Zhengzhou, 450003, China. Electronic address: [email protected]
,
(China)
- Type
- Published Article
- Journal
-
Cancer letters
- Publication Date
-
Mar 01, 2020
- Volume
-
472
- Pages
-
165–174
- Identifiers
-
DOI: 10.1016/j.canlet.2019.12.019
-
PMID: 31857156
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application. Copyright © 2019 Elsevier B.V. All rights reserved.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 08/13/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/31857156
